Capnia, Inc

Embracing Innovation: Transforming Hyperbilirubinemia Management with CoSense ETCOc Technology. The CoSense ETCOc Monitor performs a non-invasive, bedside breath test using a nasal cannula, and identifies hemolysis and neurotoxic risks from rising unconjugated bilirubin, aiming to prevent hemolytic HB and Kernicterus. Grounded in extensive research, peer-reviewed studies, and neonatology expert endorsements, CoSense revolutionizes neonatal care by enabling precise, customized interventions, including vigilant monitoring and effective phototherapy, setting new care standards in neonatology

Neonatal,health care devices,respiratory support,medical instruments systems,mother-baby,newborn care,pediatrics,jaundice management,and well-baby nursery

Capnia, inc operates in the Medical device industry.

Capnia, inc's revenue is 11m - 100m

Capnia, inc has 11 - 50 employees.